Sònia Añor

Dr. Sònia Añor


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
VHVirginia Haurigot
Virginia Haurigot
SMSara Marcó
Sara Marcó
ARAlbert Ribera
Albert Ribera
MGMiguel Garcia
Miguel Garcia
ARAlbert Ruzo
Albert Ruzo
FBFatima Bosch
Fatima Bosch
For most lysosomal storage diseases (LSDs) affecting the CNS, there is currently no cure. The BBB, which limits the bioavailability of drugs administered systemically, and the short half-life of lysosomal enzymes, hamper the development of effective therapies. Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomic recessive LSD caused by a deficiency in sulfamidase, a sulfatase involved in the stepwise degradation of glycosaminoglycan (GAG) heparan sulfate. Here, we demonstrate that intracerebrospinal fluid (intra-CSF) administration of serotype 9 adenoassociated viral vectors (AAV9s) encoding sulfamidase corrects both CNS and somatic pathology in MPS IIIA mice. Following vector administration, enzymatic activity increased throughout the brain and in serum, leading to whole body correction of GAG accumulation and lysosomal pathology, normalization of behavioral deficits, and prolonged survival. To test this strategy in a larger animal, we treated beagle dogs using intracisternal or intracerebroventricular delivery. Administration of sulfamidase-encoding AAV9 resulted in transgenic expression throughout the CNS and liver and increased sulfamidase activity in CSF. High-titer serum antibodies against AAV9 only partially blocked CSF-mediated gene transfer to the brains of dogs. Consistently, anti-AAV antibody titers were lower in CSF than in serum collected from healthy and MPS IIIA–affected children. These results support the clinical translation of this approach for the treatment of MPS IIIA and other LSDs with CNS involvement.

1 January 2011 in The Veterinary Journal
Verified
Journal Article
Closed access
SRSergio Ródenas
Sergio Ródenas
MPMarti Pumarola
Marti Pumarola
LGLluís Gaitero
Lluís Gaitero
ÀZÀngels Zamora
Àngels Zamora
SASònia Añor
Sònia Añor

12 June 2021 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
Roberto José-LópezRoberto José-López
Roberto José-López
RGRodrigo Gutierrez-Quintana
Rodrigo Gutierrez-Quintana
CFCristian de la Fuente
Cristian de la Fuente
EMEdgar G. Manzanilla
Edgar G. Manzanilla
ASAnna Suñol
Anna Suñol
MPMartí Pumarola
Martí Pumarola
Background Gliomas in dogs remain poorly understood. Objectives To characterize the clinicopathologic findings, diagnostic imaging features and survival of a large sample of dogs with glioma using the Comparative Brain Tumor Consortium diagnostic classification. Animals Ninety-one dogs with histopathological diagnosis of glioma. Methods Multicentric retrospective case series. Signalment, clinicopathologic findings, diagnostic imaging characteristics, treatment, and outcome were used. Tumors were reclassified according to the new canine glioma diagnostic scheme. Results No associations were found between clinicopathologic findings or survival and tumor type or grade. However, definitive treatments provided significantly (P = .03) improved median survival time (84 days; 95% confidence interval [CI], 45-190) compared to palliative treatment (26 days; 95% CI, 11-54). On magnetic resonance imaging (MRI), oligodendrogliomas were associated with smooth margins and T1-weighted hypointensity compared to astrocytomas (odds ratio [OR], 42.5; 95% CI, 2.42-744.97; P = .04; OR, 45.5; 95% CI, 5.78-333.33; P < .001, respectively) and undefined gliomas (OR, 84; 95% CI, 3.43-999.99; P = .02; OR, 32.3; 95% CI, 2.51-500.00; P = .008, respectively) and were more commonly in contact with the ventricles than astrocytomas (OR, 7.47; 95% CI, 1.03-53.95; P = .049). Tumor spread to neighboring brain structures was associated with high-grade glioma (OR, 6.02; 95% CI, 1.06-34.48; P = .04). Conclusions and Clinical Importance Dogs with gliomas have poor outcomes, but risk factors identified in survival analysis inform prognosis and the newly identified MRI characteristics could refine diagnosis of tumor type and grade.

16 October 2006 in Journal of Comparative Pathology
Verified
Journal Article
Closed access
PMP. Montoliu
P. Montoliu
SASònia Añor
Sònia Añor
Enric VidalEnric Vidal
Enric Vidal
MPMartí Pumarola
Martí Pumarola

1 July 2008 in Journal of Comparative Pathology
Verified
Journal Article
Closed access
LGL. Gaitero
L. Gaitero
SASònia Añor
Sònia Añor
DFD. Fondevila
D. Fondevila
MPMartí Pumarola
Martí Pumarola

18 December 2014 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ARAlbert Ribera
Albert Ribera
VHVirginia Haurigot
Virginia Haurigot
MGMiguel Garcia
Miguel Garcia
SMSara Marcó
Sara Marcó
SMSandra Motas
Sandra Motas
FBFatima Bosch
Fatima Bosch
Gene therapy is an attractive tool for the treatment of monogenic disorders, in particular for lysosomal storage diseases (LSD) caused by deficiencies in secretable lysosomal enzymes in which neither full restoration of normal enzymatic activity nor transduction of all affected cells are necessary. However, some LSD such as Mucopolysaccharidosis Type IIIB (MPSIIIB) are challenging because the disease's main target organ is the brain and enzymes do not efficiently cross the blood–brain barrier even if present at very high concentration in circulation. To overcome these limitations, we delivered AAV9 vectors encoding for α-N-acetylglucosaminidase (NAGLU) to the Cerebrospinal Fluid (CSF) of MPSIIIB mice with the disease already detectable at biochemical, histological and functional level. Restoration of enzymatic activity in Central Nervous System (CNS) resulted in normalization of glycosaminoglycan content and lysosomal physiology, resolved neuroinflammation and restored the pattern of gene expression in brain similar to that of healthy animals. Additionally, transduction of the liver due to passage of vectors to the circulation led to whole-body disease correction. Treated animals also showed reversal of behavioural deficits and extended lifespan. Importantly, when the levels of enzymatic activity were monitored in the CSF of dogs following administration of canine NAGLU-coding vectors to animals that were either naïve or had pre-existing immunity against AAV9, similar levels of activity were achieved, suggesting that CNS efficacy would not be compromised in patients seropositive for AAV9. Our studies provide a strong rationale for the clinical development of this novel therapeutic approach as the treatment for MPSIIIB.